Research programme: transdermal therapeutics - Aequus Pharmaceuticals

Drug Profile

Research programme: transdermal therapeutics - Aequus Pharmaceuticals

Alternative Names: AQS 1302; AQS 1304; Cannabinoid transdermal delivery system; Clobazam transdermal patch

Latest Information Update: 08 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aequus Pharmaceuticals
  • Class Antidementias; Antiemetics; Antiepileptic drugs; Anxiolytics; Benzodiazepines; Cannabinoids; Picolines; Pyridines; Sedating antihistamines; Small molecules; Vitamins
  • Mechanism of Action Biogenic monoamine uptake modulators; Cannabinoid receptor modulators; GABA A receptor agonists; Histamine H1 receptor antagonists; Neurotransmitter stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Epilepsy; Nausea

Most Recent Events

  • 01 May 2017 Preclinical trials in Alzheimer's disease in Canada (Transdermal) before May 2017 (Aequus Pharmaceuticals website, May 2017)
  • 02 Mar 2017 Aequus Pharmaceuticals enters into a binding term sheet agreement for worldwide exclusive license of cannabinoid transdermal patch for Neurological disorders
  • 05 Aug 2016 Research programme: transdermal therapeutics - Aequus Pharmaceuticals is available for licensing in World as of 05 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top